loe-exposure
Drug patent expiries ranked by the Medicare Part D spending exposed to them
我該用這個嗎
品質與安全性
A
根據工具定義與協定合規性的自動化分析。
上下文成本
~180Token（工具定義）
~606 B典型回應大小
極小的注意力影響（128k 上下文的 0.14%）
這是每次將伺服器的工具載入模型上下文時所消耗的約略 token 數量。數量越高，可用於其他工作的注意力就越少。
安裝
一鍵安裝
將以下內容加入你的 `claude_desktop_config.json` 檔案：
{
"mcpServers": {
"loe-exposure": {
"url": "https://rxfinder.ai/mcp"
}
}
}遠端端點
https://rxfinder.ai/mcpstreamable-http它能做什麼
工具清單
工具（1）
🟢 唯讀🟡 寫入🔴 刪除⚪ 未知
🟢loss_of_exclusivity_exposure(window, limit)
Rank upcoming FDA Orange Book patent and exclusivity expiries BY the gross Medicare Part D spending exposed to them, with marketed-generic status for each ranked drug resolved from live CMS NADAC price evidence. Answers which expiries matter, not merely which come first. Reports EXPOSURE, never forecast savings. Spending is gross of manufacturer rebates. Orange Book small molecules only, so biologics — among the largest Part D line items — are excluded, and the headline total must not be read as spending that will "go generic".
輸入結構描述
{
"type": "object",
"properties": {
"window": {
"type": "string",
"description": "Months ahead to include, default 24"
},
"limit": {
"type": "string",
"description": "How many drugs to rank, default 25"
}
},
"required": []
}社群
證據
近期觀測
已驗證未記錄版本1 個工具
已驗證未記錄版本1 個工具
已驗證未記錄版本1 個工具